Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Larimar Therapeutics (LRMR) Shares Outstanding (2016 - 2020)

Larimar Therapeutics (LRMR) has disclosed Shares Outstanding for 7 consecutive years, with $6.1 million as the latest value for Q3 2019.

  • For the quarter ending Q3 2019, Shares Outstanding fell 83.48% year-over-year to $6.1 million, compared with a TTM value of $6.1 million through Sep 2019, down 83.48%, and an annual FY2018 reading of $37.3 million, up 35.64% over the prior year.
  • Shares Outstanding was $6.1 million for Q3 2019 at Larimar Therapeutics, roughly flat from $6.1 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $36.9 million in Q3 2018 and bottomed at $6.1 million in Q4 2018.
  • Average Shares Outstanding over 5 years is $19.8 million, with a median of $27.3 million recorded in 2015.
  • The sharpest move saw Shares Outstanding increased 19.07% in 2015, then tumbled 83.48% in 2019.
  • Year by year, Shares Outstanding stood at $27.2 million in 2015, then rose by 0.33% to $27.3 million in 2016, then increased by 0.57% to $27.5 million in 2017, then crashed by 77.84% to $6.1 million in 2018, then changed by 0.0% to $6.1 million in 2019.
  • Business Quant data shows Shares Outstanding for LRMR at $6.1 million in Q3 2019, $6.1 million in Q2 2019, and $6.1 million in Q1 2019.